Radiation recall dermatitis with abemaciclib developing a year after radiotherapy
Importance: Cyclin-dependent kinases 4/6 (CDK4/6) inhibitors had been recently introduced in clinical practice approved for use in hormone receptor (HR) positive/ human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer. We report the first incidence of radiation...
Main Authors: | Archya Dasgupta, Francis Patafio, Hany Soliman, Arjun Sahgal, Maureen Trudeau, Gregory J. Czarnota |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-03-01
|
Series: | Current Problems in Cancer: Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S266662192100003X |
Similar Items
-
Profile of abemaciclib and its potential in the treatment of breast cancer
by: Martin JM, et al.
Published: (2018-08-01) -
CDK 4/6 inhibitors combined with radiotherapy: A review of literature
by: Claire Bosacki, et al.
Published: (2021-01-01) -
Efficiency and tolerability of abemaciclib in elderly patients
by: E. I. Kovalenko, et al.
Published: (2020-12-01) -
Safety of palbociclib concurrent with palliative pelvic radiotherapy: discussion of a case of increased toxicity and brief review of literature
by: Archya Dasgupta, et al.
Published: (2021-03-01) -
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
by: Patrick Neven, et al.
Published: (2021-08-01)